Johnson & Johnson (NYSE:JNJ) Price Target Raised to $275.00 at The Goldman Sachs Group

Johnson & Johnson (NYSE:JNJ) had its target price upped by The Goldman Sachs Group from $265.00 to $275.00 in a report issued on Wednesday,MarketScreener reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 15.05% from the stock’s previous close.

A number of other research analysts have also recently commented on JNJ. JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, March 5th. Argus raised their price objective on Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. Guggenheim upped their target price on shares of Johnson & Johnson from $240.00 to $244.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Loop Capital set a $220.00 price target on shares of Johnson & Johnson in a research note on Tuesday, January 27th. Finally, Stifel Nicolaus set a $250.00 target price on shares of Johnson & Johnson in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $247.48.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $239.03 on Wednesday. The stock has a 50 day moving average price of $241.58 and a 200 day moving average price of $216.38. The stock has a market cap of $575.74 billion, a PE ratio of 21.67, a P/E/G ratio of 2.37 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a one year low of $146.12 and a one year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period last year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 1,322 shares of Johnson & Johnson stock in a transaction on Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,142 shares of company stock worth $7,360,528 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of JNJ. Blueline Advisors LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth about $25,000. Abich Financial Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $26,000. Cresta Advisors Ltd. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $26,000. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at $28,000. Finally, DecisionPoint Financial LLC grew its position in Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q1 beat and guidance lift — J&J reported $2.70 EPS vs. ~$2.68 expected and $24.06B revenue, then raised FY2026 sales and EPS outlook, which supports higher multiple and investor confidence. Johnson & Johnson Q1 2026 Earnings Call Transcript
• Positive Sentiment: Dividend raise reinforces income thesis — Board increased the quarterly payout to $1.34 (64th consecutive annual increase), supporting yield-oriented investors and reducing downside volatility. Business Wire: Dividend Increase
• Positive Sentiment: Commercial drivers: oncology and new therapies — Strong sales from Darzalex, Tremfya and Spravato (notable QoQ and YoY growth) underpin the raised outlook and signal sustainable growth beyond legacy products. Yahoo Finance: Raises 2026 Outlook
• Neutral Sentiment: Analyst commentary and sentiment — Some bullish takes argue upside (e.g., a MarketBeat piece saying a ~20% gain looks achievable), while others caution valuation vs. growth peers; watch analyst revisions post‑call. MarketBeat: 20% Gain Thesis
• Neutral Sentiment: Media/broker notes highlight sector implications — J&J’s results are being read as a signal for healthcare ETFs and psychedelics peers (Spravato strength), which may amplify flows into/away from JNJ depending on broader sector moves. ETF Trends: Sector Implications
• Negative Sentiment: Profit decline, cash‑flow and margin pressure — Despite top‑line beats, Q1 profit fell and free cash flow reportedly declined, which raises near‑term margin and cash concerns. RTTNews: Profit Down
• Negative Sentiment: Stelara decline & biosimilar risk — A steep drop in Stelara sales and ongoing biosimilar competition for legacy drugs remain a headwind and a source of uncertainty for sustaining past revenue levels. Reuters: Stelara Sales Disappoint
• Negative Sentiment: Mixed market reaction — Some coverage notes the stock initially slipped despite the beat, reflecting investor focus on margins, modest guidance details versus expectations and rotation within the sector. Investors Business Daily: Early Slip

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.